Available Information
Disc announces material information to the public about the Company, its products and services, and other matters through a variety of means, including filings
with the U.S. Securities and Exchange Commission (SEC), press releases, public conference calls, webcasts and the investor relations section of the Company website at ir.discmedicine.com in order to achieve broad,
non-exclusionary distribution of information to the public and for complying with its disclosure obligations under Regulation FD.
Disc Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but
not limited to, express or implied statements regarding Discs expectations with respect to its AURORA Phase 2 and BEACON Phase 2 clinical studies of bitopertin and the results thereof, and its Phase 1b/2 study of bitopertin in Diamond-Blackfan
Anemia, its Phase 1b/2 clinical studies of DISC-0974 in patients with MF and NDD-CKD patients with anemia, its Phase 1 clinical study of DISC-3405 in healthy volunteers; projected timelines for the initiation
and completion of its clinical trials, anticipated timing of release of data, and other clinical activities; and Discs business plans and objectives; and Discs beliefs about operating expenses and that it will have capital to fund Disc
well into 2026. The use of words such as, but not limited to, believe, expect, estimate, project, intend, future, potential, continue, may,
might, plan, will, should, seek, anticipate, or could or the negative of these terms and other similar words or expressions that are intended to identify
forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on Discs current beliefs, expectations and assumptions regarding the future of Discs
business, future plans and strategies, clinical results and other future conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed
or implied) are made about the accuracy of any such forward-looking statements.
Disc may not actually achieve the plans, intentions or expectations
disclosed in these forward-looking statements, and investors should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the
forward-looking statements as a result of a number of material risks and uncertainties including but not limited to: the adequacy of Discs capital to support its future operations and its ability to successfully initiate and complete clinical
trials; the nature, strategy and focus of Disc; the difficulty in predicting the time and cost of development of Discs product candidates; Discs plans to research, develop and commercialize its current and future product candidates; that
enrollment timelines of both the BEACON and AURORA studies may not necessarily be predictive of future enrollment timelines; the timing of initiation of Discs planned clinical trials; Discs ability to retain and recognize the intended
incentives conferred by Fast Track Designation for its product candidates including DISC-3405; the timing of the availability of data from Discs clinical trials; Discs ability to identify additional product candidates with significant
commercial potential and to expand its pipeline in hematological diseases; the timing and anticipated results of Discs preclinical studies and clinical trials and the risk that the results of Discs clinical trials may not be predictive
of future results in connection with future studies or clinical trials and may not support further development and marketing approval; the other risks and uncertainties described